Investors were still buying it in the afterglow of its latest quarterly earnings release.

A personalized melanoma vaccine could prevent recurrence and fuel Merck’s growth.

Merck's revenue rose in Q3 as Keytruda and Winrevair sales climbed, but overbought signals point to a pullback. Click for ...

Merck (MRK) stock returned 69.6% over the year to October 8, 2026, against 16.3% for the S&P 500. The gain built up over a year of drug approvals and clinical trial results, arriving just as the ...

After strong gains recorded in the previous session following a late-stage trial success for a cancer vaccine developed with Moderna (MRNA), Merck (MRK) slipped on Thursday as RBC Capital Markets ...

Merck came into this Q3 2026 earnings print with the stock already on a steady climb, up about 15% over the past three months ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Merck shares soared 87% over the past year, significantly outperforming peers, as investors ...

Merck & Co. stock enters the weekend after stronger third-quarter sales and a higher 2026 outlook. Pipeline data add another ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, has been notified that TRC Capital Investment Corporation (TRC Capital) has commenced an unsolicited “mini-tender” offer, dated ...